PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION

Background: The importance of economic evaluation in decision making is growing with increasing budgetary pressures on health systems. Diverse economic evidence is available for a range of interventions across national contexts within Europe, but little attention has been given to identifying evidence gaps that, if filled, could contribute to more efficient allocation of resources. One objective of the Research Agenda for Health Economic Evaluation project is to determine the most important methodological evidence gaps for the ten highest burden conditions in the European Union (EU), and to suggest ways of filling these gaps. Methods: The highest burden conditions in the EU by Disability Adjusted Life Years were determined using the Global Burden of Disease study. Clinical interventions were identified for each condition based on published guidelines, and economic evaluations indexed in MEDLINE were mapped to each intervention. A panel of public health and health economics experts discussed the evidence during a workshop and identified evidence gaps. Results: The literature analysis contributed to identifying cross-cutting methodological and technical issues, which were considered by the expert panel to derive methodological research priorities. Conclusions: The panel suggests a research agenda for health economics which incorporates the use of real-world evidence in the assessment of new and existing interventions; increased understanding of cost-effectiveness according to patient characteristics beyond the “-omics” approach to inform both investment and disinvestment decisions; methods for assessment of complex interventions; improved cross-talk between economic evaluations from health and other sectors; early health technology assessment; and standardized, transferable approaches to economic modeling.

[1]  P. Gøtzsche,et al.  “Adaptive pathways” to drug authorisation: adapting to industry? , 2016, British Medical Journal.

[2]  P. Cuijpers,et al.  Economic evidence for the clinical management of major depressive disorder: a systematic review and quality appraisal of economic evaluations alongside randomised controlled trials , 2016, Epidemiology and Psychiatric Sciences.

[3]  D. Cohen Attacks on publicly funded trials: what happens when industry does not want to know the answer , 2015, BMJ : British Medical Journal.

[4]  M. Miravitlles,et al.  Economic valuation and determinants of informal care to disabled people with Chronic Obstructive Pulmonary Disease (COPD) , 2015, BMC Health Services Research.

[5]  Karl Claxton,et al.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.

[6]  G. Pietri,et al.  Market Access and Reimbursement: The Increasing Role of Real-World Evidence. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  J. Jansson,et al.  External validity of the ARISTOTLE trial in real-life atrial fibrillation patients. , 2014, Cardiovascular therapeutics.

[8]  MayPeter,et al.  Economic Impact of Hospital Inpatient Palliative Care Consultation: Review of Current Evidence and Directions for Future Research , 2014 .

[9]  M. Stevenson,et al.  Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review , 2014, Current Rheumatology Reports.

[10]  A. Woodcock,et al.  Obtaining real-world evidence: the Salford Lung Study , 2014, Thorax.

[11]  A. Brennan,et al.  Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  D. Tashkin,et al.  Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease , 2013, Respiratory Research.

[13]  A. Brennan,et al.  Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community , 2013, BMC Health Services Research.

[14]  Chris Salisbury,et al.  Implications of comorbidity for primary care costs in the UK: a retrospective observational study. , 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.

[15]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[17]  Bernadette A. Thomas,et al.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[18]  Hazel Squires,et al.  Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  S. Wyke,et al.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.

[20]  L. Radbruch,et al.  Enhancing patient-reported outcome measurement in research and practice of palliative and end-of-life care , 2012, Supportive Care in Cancer.

[21]  J. Kang,et al.  Anti-Obesity Drugs: A Review about Their Effects and Safety , 2012, Diabetes & metabolism journal.

[22]  P. Oh,et al.  Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada , 2011, BMC health services research.

[23]  R. Holle,et al.  Multimorbidity and health-related quality of life in the older population: results from the German KORA-Age study , 2011, Health and quality of life outcomes.

[24]  S. Simoens Pricing and reimbursement of orphan drugs: the need for more transparency , 2011, Orphanet journal of rare diseases.

[25]  I. Higginson,et al.  Implementing patient reported outcome measures (PROMs) in palliative care - users' cry for help , 2011, Health and quality of life outcomes.

[26]  M. Sculpher,et al.  Bridging the gap between methods research and the needs of policy makers: A review of the research priorities of the National Institute for Health and Clinical Excellence , 2011, International Journal of Technology Assessment in Health Care.

[27]  K. Tham,et al.  Combined life satisfaction of persons with stroke and their caregivers: associations with caregiver burden and the impact of stroke , 2011, Health and quality of life outcomes.

[28]  W. Brouwer,et al.  Willingness to pay for a quality-adjusted life-year: the individual perspective. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  Reinhard Busse,et al.  Tackling Chronic Disease in Europe: Strategies, Interventions and Challenges , 2010 .

[30]  R. Ferner,et al.  New drugs for old: disinvestment and NICE , 2010, BMJ : British Medical Journal.

[31]  Kristian Lampe,et al.  Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA , 2009, International Journal of Technology Assessment in Health Care.

[32]  K. Chalkidou,et al.  Comparative effectiveness research priorities: Identifying critical gaps in evidence for clinical and health policy decision making , 2009, International Journal of Technology Assessment in Health Care.

[33]  J. Coast,et al.  Use of economic evaluation in local health care decision-making in England: a qualitative investigation. , 2009, Health policy.

[34]  J. Hiller,et al.  Exploring policy-makers’ perspectives on disinvestment from ineffective healthcare practices , 2008, International Journal of Technology Assessment in Health Care.

[35]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[36]  J. Hiller,et al.  Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices , 2007, Australia and New Zealand health policy.

[37]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.

[38]  P. Littlejohns,et al.  Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service? , 2007, Journal of health services research & policy.

[39]  K. Khunti,et al.  The prevalence of co‐morbid depression in adults with Type 2 diabetes: a systematic review and meta‐analysis , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[40]  R. Baltussen,et al.  Priority setting of health interventions: the need for multi-criteria decision analysis , 2006, Cost effectiveness and resource allocation : C/E.

[41]  James Christie,et al.  Economic evaluation databases as an aid to healthcare decision makers and researchers , 2005, Expert review of pharmacoeconomics & outcomes research.

[42]  P. Buser,et al.  Incremental Cost-Effectiveness of Drug-Eluting Stents Compared With a Third-Generation Bare-Metal Stent in a Real-World Setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET) , 2005 .

[43]  Christoph Kaiser,et al.  Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET) , 2005, The Lancet.

[44]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[45]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[46]  S. Currie,et al.  Chronic back pain and major depression in the general Canadian population , 2004, Pain.

[47]  Richard Birtwhistle,et al.  Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. , 2003, BMC medical research methodology.

[48]  D. Banta The development of health technology assessment. , 2003, Health policy.

[49]  Laura E. Gibbons,et al.  Assessing Quality of Life in Older Adults With Cognitive Impairment , 2002, Psychosomatic medicine.

[50]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[51]  L. Abenhaim,et al.  Smoking. A risk factor for development of low back pain in adolescents. , 1999, Spine.

[52]  S. Hecht,et al.  Tobacco smoke carcinogens and lung cancer. , 1999, Journal of the National Cancer Institute.

[53]  C Bain,et al.  Threats to Applicability of Randomised Trials: Exclusions and Selective Participation , 1999, Journal of health services research & policy.

[54]  J. Coebergh,et al.  Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. , 1998, Lung cancer.

[55]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[56]  A. Forster,et al.  Incidence and consequences offalls due to stroke: a systematic inquiry , 1995, BMJ.

[57]  W C Willett,et al.  A prospective study of exercise and incidence of diabetes among US male physicians. , 1992, JAMA.

[58]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[59]  R B D'Agostino,et al.  Cigarette smoking as a risk factor for stroke. The Framingham Study. , 1988, JAMA.

[60]  Karl Claxton,et al.  Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? , 2015, Health economics.

[61]  Pepijn Vemer,et al.  RESEARCH AGENDA FOR HEALTH ECONOMIC EVALUATION , 2014 .

[62]  R. Morrison,et al.  Economic impact of hospital inpatient palliative care consultation: review of current evidence and directions for future research. , 2014, Journal of palliative medicine.

[63]  M. Suhrcke,et al.  The economics of the social determinants of health and health inequalities: a resource book , 2013 .

[64]  A. Harris,et al.  Cost-Effectiveness Analysis and the Consistency of Decision Making , 2012, PharmacoEconomics.

[65]  M. Buxton,et al.  Economic Evaluation and Decision Making in the UK , 2012, PharmacoEconomics.

[66]  Financial Affairs Joint report on health systems , 2010 .

[67]  Elias Mossialos,et al.  Financing health care in the European Union: challenges and policy responses , 2009 .

[68]  M. Neyt,et al.  Threshold values for cost-effectiveness in health care KCE reports , 2009 .